Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-02-08
2011-02-08
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S278000, C544S099000, C546S017000
Reexamination Certificate
active
07884099
ABSTRACT:
The compounds include substituted rifamycin derivatives in which a quinolone carboxylic acid pharmacophore is covalently bonded to a benzoxazinorifamycin or a spiropiperidinorifamycin. The rifamycin derivatives are useful as antimicrobial agents and are effective against a number of human and veterinary Gram positive and Gram negative pathogens. The advantage of the inventive compounds is that both the rifamycin and quinolone antibacterial pharmacophores are co-delivered with matched pharmacokinetics to the targeted pathogens of interests. Delivery of multiple antibacterial pharmacophores simultaneously to the targeted pathogens has the maximum chance of achieving synergy and minimizing the development of resistance to the antibiotics given.
REFERENCES:
patent: 4165317 (1979-08-01), Rossetti et al.
patent: 4219478 (1980-08-01), Marsili et al.
patent: 4563459 (1986-01-01), Grohe et al.
patent: 4620007 (1986-10-01), Grohe et al.
patent: 4983602 (1991-01-01), Yamane et al.
patent: 5880283 (1999-03-01), Matsumoto et al.
patent: 2005/0137189 (2005-06-01), van Duzer et al.
patent: 2005/0209210 (2005-09-01), Ding et al.
patent: 2005/0256096 (2005-11-01), Combrink et al.
patent: 2005/0261262 (2005-11-01), Ma et al.
patent: 2006/0019985 (2006-01-01), Ma et al.
patent: 2006/0019986 (2006-01-01), Ding et al.
patent: 0 333 176 (1989-09-01), None
patent: 1 603 127 (1981-11-01), None
patent: WO 02/102792 (2002-12-01), None
patent: WO 03/045319 (2003-06-01), None
patent: WO 2006/012443 (2006-02-01), None
patent: WO 2007/056086 (2007-05-01), None
patent: WO 2007/070613 (2007-06-01), None
Hamilton-Miller, JMT, “Dual-action antibiotic hybrids” Journal of Antimicrobiol Chemotherapy, 1994, vol. 33, No. 2, pp. 197-200, US.
International Search Report , European Patent Office, Mar. 4, 2009.
Farr, B. M., Rifamycins, in Principles and Practice of Infectious Diseases, Mandell, G. L., Bennett, J. E., Dolin, R., Eds.; Churchhill Livingstone: Philadelphia; p. 348-361, 2000.
Helv. Chim. Acta., 1973, 56, p. 2369.
European Patent Office, International Preliminary Report on Patentability, Serial No. PCT/US2008/083246, Feb. 15, 2010.
Karchmer, A. W. et al: “Rifampin treatment of Prosthetic Valve Endocarditis Due to Staphylococcus epidermidis” Rev. Infect. Dis. 5 (S3): p. S543-548 (1983).
Kaufman C. A. et al: “Increasing resistance ofStaphylococcus aureusto ciprofloxacin” Antimicrob Agents Chemother. Sep. 1990 34(9):1862-3.
National Committee for Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA 2000.
Watanakunakorn, C, “Interaction of Vancomycin and Rifampin AgainstStaphyloccocus aureus,” Antimicrob. Agents & Chemother. 19(6): p. 1089-1091 (1981).
Yajko, D. M. et al: “In Vitro Susceptibility ofMycobacteriumavium Complex to the New Fluoroquinolone Sparfloxacin and Comparison with Ciprofloxacin” Antimicrob. Agents & Chemother. 34(12): p. 2442-2444 (1990).
Combrink Keith
Ding Charles Z.
Jin Yafei
Kim In Ho
Cumbre IP Ventures, L.P.
Jackson Walker L.L.P.
Kifle Bruck
LandOfFree
Quinolone carboxylic acid-substituted rifamycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Quinolone carboxylic acid-substituted rifamycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinolone carboxylic acid-substituted rifamycin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649011